Teduglutide (GLP-2)
Also known as: GLP-2 analog, Gattex, Revestive, Glucagon-like peptide-2
Teduglutide is a GLP-2 (glucagon-like peptide-2) analog that promotes intestinal mucosal growth and function, FDA-approved for short bowel syndrome research and treatment.
Key Findings at a Glance
- • Teduglutide is the only GLP-2 receptor agonist approved by the FDA, specifically indicated for short bowel syndrome where it can reduce or eliminate the need for intravenous nutrition.
- • Unlike GLP-1 peptides that suppress appetite and promote weight loss, teduglutide promotes intestinal villus growth and increases the absorptive surface area of the remaining gut.
- • A single amino acid substitution from alanine to glycine at position 2 makes teduglutide resistant to DPP-4 enzyme degradation, extending its half-life from 7 minutes to about 2 hours.
- • Teduglutide has demonstrated the ability to reduce parenteral nutrition requirements by 20 percent or more in clinical trials, fundamentally improving quality of life for short bowel syndrome patients.
Teduglutide (GLP-2) Overview & Molecular Profile
Teduglutide is a recombinant analog of human GLP-2 with a single amino acid substitution (alanine-to-glycine at position 2) that confers resistance to DPP-4 degradation, extending its half-life from 7 minutes to approximately 2 hours. Unlike GLP-1, which primarily affects glucose metabolism and appetite, GLP-2 specifically targets the gastrointestinal tract to promote intestinal mucosal growth and nutrient absorption. FDA-approved as Gattex for short bowel syndrome, teduglutide can reduce parenteral nutrition dependence. Research applications also include inflammatory bowel disease and chemotherapy-induced mucositis.
Mechanism of Action: Receptor Agonism & Metabolic Pathways
Teduglutide activates GLP-2 receptors expressed on intestinal subepithelial myofibroblasts, enteric neurons, and enteroendocrine cells, triggering multiple downstream effects that promote intestinal health. Receptor activation increases crypt cell proliferation and reduces apoptosis, leading to expansion of absorptive surface area through villus growth and crypt hyperplasia. The peptide enhances intestinal blood flow, stimulates release of intestinal growth factors including IGF-1 and EGF, and modulates intestinal permeability. Unlike native GLP-2, the alanine-to-glycine substitution prevents DPP-4 cleavage, allowing sustained receptor activation with once-daily dosing.
Teduglutide Pharmacokinetics: GLP-2 Analog for Once-Daily Intestinal Support
Teduglutide achieves a plasma half-life of approximately 2 hours through its single amino acid substitution (alanine-to-glycine at position 2) that confers resistance to DPP-4 degradation — a 17-fold improvement over native GLP-2's 7-minute half-life. This engineered stability enables effective once-daily subcutaneous dosing for sustained intestinal trophic support.
Absorption and Half-Life
- • Plasma half-life of approximately 2 hours following subcutaneous injection at the approved dose of 0.05 mg/kg/day — a 17-fold extension over native GLP-2 (t½ ~7 minutes).
- • The alanine-to-glycine substitution at position 2 renders teduglutide resistant to DPP-4 cleavage, the primary degradation pathway that limits native GLP-2 to a 7-minute plasma presence.
- • Complete bioavailability by the subcutaneous route, with peak plasma concentration (Cmax ~20 ng/mL) reached within 3-5 hours of injection.
- • Weight-based dosing (0.05 mg/kg) requires recalculation every 6 months as body weight changes during treatment; dose reduction by 50% is recommended in severe renal impairment (CrCl <30 mL/min).
Intestinal Trophic Effects
- • The intestinal mucosal growth response to teduglutide far outlasts its 2-hour plasma half-life — villus height increases, crypt hyperplasia, and enhanced absorptive capacity develop progressively over 3-6 months of daily dosing.
- • Once-daily administration maintains sufficient GLP-2 receptor activation throughout the day to sustain crypt cell proliferation and reduce mucosal apoptosis.
- • Citrulline levels (a biomarker of functional intestinal mass) continue to rise over months of treatment, confirming that brief daily receptor activation triggers durable structural intestinal adaptation.
- • The STEPS trial demonstrated that 63% of patients achieved at least 20% reduction in parenteral nutrition requirements at 24 weeks, with benefits maintained and even improving through 30 months of continued daily dosing.
Teduglutide Pharmacokinetics: SC Injection Plasma Concentration Profile
Figure: Teduglutide (blue) achieves sustained plasma levels with Tmax at ~3.5 hours and a 2-hour half-life, enabling once-daily dosing. Native GLP-2 (red dashed) is degraded by DPP-4 within minutes (t½ ~7 min). The Gly2 substitution provides a 17-fold half-life extension. Based on FDA-approved Gattex prescribing data.
Research-Observed Effects
Intestinal Mucosal Growth
Extensive ResearchClinical studies demonstrate significant intestinal adaptation with teduglutide treatment, including increased villus height, crypt depth, and overall mucosal surface area measured by histological analysis and citrulline levels. Research in short bowel syndrome patients shows progressive improvement in intestinal absorptive capacity, with benefits typically emerging over 3-6 months of treatment. Studies document enhanced expression of nutrient transporters and digestive enzymes in treated patients. The trophic effects appear most pronounced in remaining small intestine and colon, promoting compensatory adaptation after resection. Animal studies reveal increased intestinal weight, protein content, and DNA synthesis with GLP-2 analog administration.
Parenteral Nutrition Reduction
Extensive ResearchClinical trials demonstrate that teduglutide enables significant reduction in parenteral nutrition (PN) requirements in short bowel syndrome patients, with many achieving complete independence from intravenous feeding. The STEPS trial program showed 63% of teduglutide-treated patients reduced PN volume by at least 20% compared to 30% with placebo. Studies document average PN reductions of 4-6 liters weekly, with some patients able to discontinue PN entirely. Research indicates that benefits persist with continued treatment and may be maintained after treatment discontinuation in some patients. These findings have transformed the management of intestinal failure, offering an alternative or complement to surgical bowel-lengthening procedures.
Intestinal Barrier Enhancement
Moderate ResearchResearch demonstrates teduglutide improves intestinal barrier function through multiple mechanisms including enhanced tight junction protein expression, increased mucus production, and reduced intestinal permeability. Studies in animal models of intestinal injury show protection against barrier breakdown and bacterial translocation. Clinical research documents reduced systemic inflammatory markers and decreased infection rates in treated patients. The barrier-enhancing effects may contribute to reduced catheter-related bloodstream infections in PN-dependent patients. These findings have implications for inflammatory bowel disease research and other conditions characterized by intestinal barrier dysfunction.
Inflammatory Bowel Disease Research
Preliminary ResearchPreclinical and early clinical studies explore teduglutide's potential in inflammatory bowel disease, particularly Crohn's disease affecting the small intestine. Animal research demonstrates reduced inflammation, enhanced mucosal healing, and improved histological scores in colitis models. The combination of trophic effects, barrier enhancement, and potential anti-inflammatory properties suggests therapeutic potential for IBD. Clinical trials are investigating teduglutide as adjunctive therapy for refractory Crohn's disease. Research also examines potential applications in ulcerative colitis and radiation-induced intestinal injury.
FDA-Approved Prescribing Information
Teduglutide (GLP-2) is an FDA-approved medication. Official prescribing information is available via the NIH National Library of Medicine DailyMed database:
Approved Dosing Summary
| Route | Dose | Frequency | Notes |
|---|---|---|---|
| Subcutaneous (Gattex/Revestive) | 0.05 mg/kg/day | Once daily | FDA-approved dose for SBS; weight-based dosing; reduce by 50% in severe renal impairment |
Dosing summary above is derived from FDA-approved prescribing information. Always refer to the official drug label for complete prescribing details, contraindications, and warnings.
Research Studies & References
Teduglutide for the Treatment of Short Bowel Syndrome (STEPS)
Jeppesen PB, Gilroy R, Pertkiewicz M, et al.
Gastroenterology (2012)
This pivotal phase 3 trial evaluated teduglutide 0.05 mg/kg daily in 86 patients with short bowel syndrome requiring parenteral nutrition. After 24 weeks, 63% of teduglutide-treated patients achieved at least 20% reduction in parenteral nutrition volume compared to 30% with placebo (p=0.002). The study documented mean PN reductions of 4.4 L/week with teduglutide versus 2.3 L/week with placebo. Secondary endpoints including citrulline levels (marker of intestinal mass) and wet weight absorption showed significant improvements. The results led to FDA approval of Gattex and established teduglutide as the first pharmacologic therapy specifically for intestinal failure rehabilitation.
Long-term safety and efficacy of teduglutide for short bowel syndrome
Schwartz LK, O'Keefe SJ, et al.
Clinical Gastroenterology and Hepatology (2016)
This long-term extension study followed patients receiving teduglutide for up to 30 months, evaluating durability of response and long-term safety. Results demonstrated sustained reductions in parenteral nutrition requirements, with progressive improvements in intestinal function over time. The study documented continued benefits in patients who initially responded, with some achieving complete PN independence. Safety analysis confirmed acceptable long-term tolerability, with most adverse events related to underlying short bowel syndrome rather than teduglutide. The findings support long-term teduglutide therapy for intestinal rehabilitation and demonstrate durability of intestinal adaptation induced by GLP-2 receptor activation.
Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome
Schwartz LK, O'Keefe SJ, Fujioka K, et al.
Clinical and Translational Gastroenterology (2016)
STEPS-2 open-label extension demonstrating sustained efficacy and safety of teduglutide over 2 years, with continued reduction in parenteral support requirements.
Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24-Week, Phase III Study
Kocoshis SA, Merritt RJ, Hill S, et al.
JPEN Journal of Parenteral and Enteral Nutrition (2020)
Phase 3 trial in pediatric patients (1-17 years) with SBS-associated intestinal failure, demonstrating teduglutide reduced parenteral support volume by ≥20% in 54% of patients at 24 weeks.
Frequently Asked Questions
How does GLP-2 differ from GLP-1?
GLP-1 and GLP-2 are both cleaved from proglucagon in intestinal L-cells and released postprandially, but activate completely different receptors with organ-specific distribution. GLP-1 receptors (GLP1R) are in the pancreas, brain, heart, kidneys, and GI tract—GLP-1 primarily controls glucose, appetite, and cardiovascular function. GLP-2 receptors (GLP2R) are concentrated in the intestinal subepithelial myofibroblasts, enteric neurons, and enteroendocrine cells—GLP-2 is specifically an intestinal trophic hormone that drives mucosal growth. This is why teduglutide (GLP-2 agonist) promotes bowel growth without the appetite suppression or glucose effects of GLP-1 agonists.
What is short bowel syndrome and why is parenteral nutrition problematic?
Short bowel syndrome (SBS) occurs when the functional intestinal length is insufficient for adequate nutrient absorption, typically following surgical resection leaving less than ~200 cm of small intestine. Parenteral nutrition (PN)—IV delivery of nutrients directly into the bloodstream—compensates but has serious long-term complications: catheter-related bloodstream infections (3–5 per 1000 catheter-days), catheter thrombosis, intestinal failure-associated liver disease (IFALD), and metabolic bone disease. PN is also extremely costly (~$150,000+/year) and profoundly affects quality of life. Reducing or eliminating PN dependence is the key clinical goal of teduglutide therapy.
Can teduglutide be used for conditions other than short bowel syndrome?
Teduglutide is FDA-approved only for SBS as of 2026, but research is active in: (1) Crohn's disease—GLP-2 receptors are expressed in inflamed bowel and GLP-2 promotes mucosal healing; (2) Chemotherapy-induced mucositis—the intestinotrophic effects may protect GI mucosa from cytotoxic drug damage; (3) Radiation enteritis—GLP-2 signaling may support recovery after pelvic radiation injury; (4) Pediatric SBS—already approved for pediatric patients (1 year and older) following pivotal trials. Each application requires GLP-2's intestinal-specific trophic effects but involves different pathological mechanisms.
Is there a concern about teduglutide promoting cancer?
Yes, this is a recognized safety consideration. GLP-2 stimulates intestinal proliferation, which raises a theoretical concern about accelerating growth of colorectal polyps or carcinomas in susceptible individuals. The FDA label requires colonoscopy within 6 months before starting teduglutide and at least every 5 years during treatment. Long-term post-marketing studies have not demonstrated a definitive increased cancer signal in SBS patients, but the patient population (older, multiple comorbidities) and limited long-term data make definitive conclusions difficult. The benefit-risk calculation in life-threatening intestinal failure (PN dependence) generally strongly favors teduglutide despite this monitoring requirement.
How does teduglutide (Gattex/Revestive) work to reduce parenteral nutrition requirements?
Teduglutide promotes intestinal adaptation—the bowel's natural ability to compensate for lost segments by increasing the absorptive capacity of remaining tissue. GLP-2 receptor activation in the intestine: (1) Increases villus height and crypt depth (enlarging the absorptive surface area); (2) Reduces mucosal cell apoptosis; (3) Promotes intestinal blood flow; (4) Slows intestinal transit (allowing more time for nutrient absorption). Over 24 weeks, these effects translate into increased fluid and macronutrient absorption, allowing clinicians to reduce IV infusion days or volume. Trial data show approximately 30–40% of patients achieve ≥20% PN reduction, and approximately 10–15% achieve complete PN independence.
What is the standard dosing and monitoring protocol for teduglutide?
Teduglutide (Gattex) is dosed at 0.05 mg/kg/day subcutaneously. Body weight changes require dose recalculation every 6 months. Monitoring requirements are specific: colonoscopy within 6 months before starting (repeated every 5 years during treatment); complete blood count (CBC) monitoring; bilirubin monitoring given the association between SBS and intestinal failure-associated liver disease. PN weaning is done gradually under dietitian/physician guidance—parenteral fluid and electrolyte volumes are reduced in increments of ~10–25% as oral/enteral tolerance improves, with blood electrolytes monitored closely to prevent volume depletion or electrolyte disorders during transition.
What was the pivotal clinical trial evidence that supported teduglutide's approval?
The STEPS trial (Study of Teduglutide Effectiveness in Parenteral Nutrition-Dependent Short Bowel Syndrome Patients) was the pivotal Phase 3 randomized controlled trial (N=86 adults) that supported FDA approval. Key results: teduglutide 0.05 mg/kg/day achieved the primary endpoint (≥20% PN reduction at week 24) in 63% of patients vs. 30% with placebo (p=0.002). PN volume reduction averaged 4.4 L/week in the teduglutide group. A 24-week extension study (STEPS-2) showed maintained PN reduction and continued improvement with ongoing treatment, supporting long-term use. These findings demonstrated clinically meaningful and statistically robust PN reduction benefits.
How does teduglutide differ from native GLP-2 and what makes it pharmaceutical-grade?
Native human GLP-2 has a plasma half-life of only 7 minutes due to rapid degradation by dipeptidyl peptidase-4 (DPP-4) at position 2 (Ala²). Teduglutide replaces the alanine at position 2 with glycine (Gly²), making it DPP-4-resistant and extending the half-life to approximately 2 hours—a 17-fold improvement enabling effective once-daily dosing. Teduglutide retains full GLP-2 receptor agonism but achieves sustained receptor activation throughout the day. This modification is analogous to how liraglutide extends native GLP-1's half-life from 2 minutes to 13 hours, and represents the core pharmaceutical engineering challenge in developing gut hormone therapeutics.
Related Peptides
View allBPC-157
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. It has been extensively studied for its potential regenerative and protective properties in various tissue types.
LL-37
LL-37 is a human cathelicidin antimicrobial peptide that plays a crucial role in innate immunity. It has broad-spectrum antimicrobial activity and immunomodulatory properties.